Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Devine, Steven M  [Clear All Filters]
2013
Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Bin Chen Y-, Kaminski MS, H Holland K, Winter JN, Mason JR, et al. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. J Clin Oncol. 2013.
2014
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, et al. High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report. JAMA Neurol. 2014.
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, et al. Lower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Leuk Lymphoma. 2014:1-20.
Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, Davis JH, Dalal JD, Devine SM, Eames GM, et al. Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease. Biol Blood Marrow Transplant. 2014.
Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, et al. Single and Multiple Dose MultiStem® (Multi-Potent Adult Progenitor Cell) Therapy Prophylaxis of Acute GVHD in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase I Trial. Biol Blood Marrow Transplant. 2014.
2015
Roddy JVF, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2015:1-5.
2019
Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, et al. BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA. Biol Blood Marrow Transplant. 2019.
Issa H, Sharma N, Zhao Q, Ruppert AS, Elder P, Benson DM, Penza S, Vasu S, William B, Jaglowski S, et al. Comparison of Two Doses of Antithymocyte Globulin in Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Biol Blood Marrow Transplant. 2019.
2020
Hamadani M, Zhang M-J, Tang X-Y, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, et al. Graft cryopreservation does not impact overall survival allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide for GVHD prophylaxis. Biol Blood Marrow Transplant. 2020.
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SOctavian, Holtzman NG, Ii GLPhillips, Devine SM, et al. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Dehn J, Chitphakdithai P, Shaw BE, McDonald AA, Devine SM, Burns LJ, Spellman S. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease and Search Prognosis. Biol Blood Marrow Transplant. 2020.
2021
Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, Steinmiller KC, Devine SM, Hutton GJ, Popat U, et al. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;54:103149.
2023
Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski SM, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, et al. Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Adv. 2023.
Magenau JM, Jaglowski SM, Uberti J, Farag SS, Riwes MMansour, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun TM, et al. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease. Blood. 2023.
Wood WA, Dilip D, Derkach A, Grover NS, Elemento O, Levine R, Thanarajasingam G, Batsis JA, Bailey C, Kannappan A, et al. Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2). PLOS Digit Health. 2023;2(1):e0000178.
2024
Stefanski HE, Kuxhausen M, Bo-Subait S, Kobusingye H, Mattila D, Schenfeld J, Sandschafer D, Burns LJ, Shaw BE, Pulsipher MA, et al. Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim. Blood Adv. 2024.